MedPath

Oral Fluid Sars-CoV-2 Ab Rapid test

Not Applicable
Completed
Conditions
Health Condition 1: A00-B99- Certain infectious and parasitic diseasesHealth Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2020/06/025674
Lead Sponsor
Diabetes Research Society
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

1. 18 years or older, men and women

2. Subjects suspected or with symptoms of Sars-CoV-2

3. Subjects, 3 days after the onset of symptoms

4. Smoking or non-smoking

5. Subjects willing for participating in the study and providing informed consent

Exclusion Criteria

Subjects on ventilators or lung support

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
There is a significant positive correlation between presence or absence of (blood and salivary) antibodies (against Sars-CoV-19 virus) and, severity and duration of disease after onset of symptoms. It is expected to initially observe this relationship most strongly in individuals who have specific disease (RT-PCR confirmed COVID-19 disease) within 7 days of onset, and these antibodies continue to remain positive in recovery period, 21 days and much later for many more weeks.Timepoint: June 16-July 31, 2020
Secondary Outcome Measures
NameTimeMethod
(blood and salivary) antibodies (against Sars-CoV-19 virus) and, severity and duration of disease after onset of symptoms. It is expected to initially observe this relationship most strongly in individuals who have specific disease (RT-PCR confirmed COVID-19 disease) within 7 days of onset, and these antibodies continue to remain positive in recovery period, 21 days and much later for many more weeks.Timepoint: June 16-July 31, 2020
© Copyright 2025. All Rights Reserved by MedPath